a Department of Medical Oncology , The First Affiliated Hospital of Bengbu Medical College , Bengbu , People's Republic of China.
b Department of Medical Oncology , PLA Cancer Center, Nanjing Bayi Hospital , Nanjing , People's Republic of China.
Cancer Biol Ther. 2018 May 4;19(5):355-358. doi: 10.1080/15384047.2018.1423917. Epub 2018 Feb 22.
Gastric carcinoma (GC) is a common gastrointestinal malignancy with high incidence and mortality worldwide, and most patients are diagnosed in the late stages of disease. Palliative chemotherapy provides a survival benefit for patients with inoperable advanced GC. However, elderly patients who are unable to tolerate chemotherapy had worse prognosis due to lack of effective treatment. Herein we reported a Chinese elderly GC patient using next generation sequencing (NGS)-based tumor DNA analysis. Valuable gene variants of vascular endothelial growth factor (VEGF) A gene amplification were detected. Additionally, a novel NOTCH1-BPHL fusion has been identified. He received antiangiogenic drug apatinib and showed both good clinical and radiographic response, but eventually died of non-cancer related cause, with progression free survival time (PFS) and overall survival time (OS) up to 9.53 months. This was the first GC case with apatinib usage as first-line treatment under the guidance of NGS gene profiling.
胃癌（GC）是一种常见的胃肠道恶性肿瘤，全球发病率和死亡率均较高，大多数患者在疾病晚期被诊断出来。对于不可切除的晚期 GC 患者，姑息性化疗可提供生存获益。然而，由于缺乏有效治疗，无法耐受化疗的老年患者预后更差。在此，我们报告了一例使用基于下一代测序（NGS）的肿瘤 DNA 分析的中国老年 GC 患者。检测到血管内皮生长因子（VEGF）A 基因扩增的有价值的基因变异。此外，还鉴定出一种新的 NOTCH1-BPHL 融合。他接受了抗血管生成药物阿帕替尼治疗，表现出良好的临床和影像学反应，但最终因非癌症相关原因死亡，无进展生存期（PFS）和总生存期（OS）长达 9.53 个月。这是首例在 NGS 基因谱指导下，使用阿帕替尼作为一线治疗的 GC 病例。
